|
|
|
Insider
Information: |
Topper James N |
Relationship: |
|
City: |
Seattle |
State: |
WA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
14 |
|
Direct
Shares |
20,715,944 |
|
Indirect Shares
|
33,777,420 |
|
|
Direct
Value |
$195,395,319 |
|
|
Indirect Value
|
$517,185,955 |
|
|
Total
Shares |
54,493,364 |
|
|
Total
Value |
$712,581,273 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
3
|
1
|
Stock
price went up :
|
0
|
1
|
Stock
price went down : |
3
|
0
|
|
|
|
Gain/Loss Ratio : |
-3.0
|
1.0
|
Percentage
Gain/Loss : |
-17.1%
|
0.5%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
La Jolla Pharmaceutical Co |
LJPC |
Director |
2005-12-14 |
0 |
2009-02-26 |
0 |
Premium* |
|
Amicus Therapeutics Inc |
FOLD |
Director, 10% Owner |
2007-06-05 |
0 |
2008-03-10 |
3,520,678 |
Premium* |
|
Portola Pharmaceuticals Inc |
PTLA |
Director |
2013-05-28 |
0 |
2013-05-28 |
1,428,954 |
Premium* |
|
Sierra Oncology Inc |
SRRA |
Director, 10% Owner |
2015-07-21 |
0 |
2017-02-14 |
8,112,121 |
Premium* |
|
Anaptysbio Inc |
ANAB |
Director |
2020-11-16 |
80,812 |
2020-11-16 |
199,529 |
Premium* |
|
Alpine Immune Sciences Inc |
ALPN |
Director |
2022-02-11 |
1,484,115 |
2024-05-18 |
0 |
Premium* |
|
Allena Pharmaceuticals, Inc. |
ALNA |
Director, 10% Owner |
2017-11-06 |
0 |
2017-11-06 |
3,330,373 |
Premium* |
|
Aptinyx Inc. |
APTX |
Director |
2018-06-25 |
0 |
2020-03-31 |
3,195,055 |
Premium* |
|
Entasis Therapeutics Holdings Inc. |
ETTX |
Director, 10% Owner |
2018-09-28 |
0 |
2018-09-28 |
1,349,953 |
Premium* |
|
Mirum Pharmaceuticals, Inc. |
MIRM |
10% Owner |
2019-07-22 |
3,566,912 |
2019-07-22 |
0 |
Premium* |
|
Arcutis Biotherapeutics, Inc. |
ARQT |
10% Owner |
2020-02-04 |
10,542,790 |
|
0 |
Premium* |
|
Passage Bio, Inc. |
PASG |
10% Owner |
2020-03-03 |
5,009,219 |
2020-03-03 |
0 |
Premium* |
|
Phathom Pharmaceuticals, Inc. |
PHAT |
|
2024-05-23 |
32,096 |
2024-05-23 |
5,831,328 |
Premium* |
|
Newamsterdam Pharma Ord Shs |
NAMS |
|
|
0 |
2024-03-26 |
6,809,429 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
95 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
LJPC |
La Jolla Pharmaceutical C... |
officerTitle |
|
2005-12-14 |
4 |
B |
$0.75 |
$15,000,000 |
I/I |
20,000,000 |
20,000,000 |
2.1 |
- |
|
SRRA |
Sierra Oncology Inc |
Director |
|
2017-02-14 |
4 |
B |
$1.35 |
$8,000,000 |
I/I |
5,925,926 |
5,925,926 |
2.25 |
- |
|
APTX |
Aptinyx Inc. |
Director |
|
2020-03-31 |
4 |
A |
$2.16 |
$10,748 |
I/I |
4,976 |
3,195,055 |
0 |
- |
|
SRRA |
Sierra Oncology Inc |
Director |
|
2015-07-21 |
4 |
A |
$5.22 |
$503,712 |
I/I |
96,589 |
1,966,195 |
0 |
- |
|
ALPN |
Alpine Immune Sciences In... |
Director |
|
2019-01-18 |
4 |
B |
$5.37 |
$1,999,997 |
I/I |
372,439 |
2,571,450 |
2.25 |
- |
|
LJPC |
La Jolla Pharmaceutical C... |
Director |
|
2007-04-04 |
4 |
B |
$6.00 |
$4,999,998 |
I/I |
833,333 |
4,833,333 |
2.1 |
- |
|
ALPN |
Alpine Immune Sciences In... |
Director |
|
2022-02-11 |
4 |
B |
$7.10 |
$799,989 |
D/D |
112,665 |
1,484,115 |
3.92 |
% |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-01 |
4 |
B |
$9.01 |
$50,729 |
I/I |
5,600 |
295,915 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-01 |
4 |
B |
$9.09 |
$296,107 |
I/I |
32,100 |
328,015 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-01-31 |
4 |
B |
$9.38 |
$60,020 |
I/I |
6,215 |
258,630 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-01 |
4 |
B |
$9.45 |
$274,739 |
I/I |
28,700 |
356,715 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-25 |
4 |
B |
$9.45 |
$93,680 |
I/I |
9,700 |
719,681 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-26 |
4 |
B |
$9.49 |
$59,252 |
I/I |
6,100 |
725,781 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-20 |
4 |
B |
$9.50 |
$476,019 |
I/I |
49,500 |
695,667 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-03-03 |
4 |
B |
$9.51 |
$422,230 |
I/I |
43,674 |
811,092 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-22 |
4 |
B |
$9.53 |
$19,197 |
I/I |
2,000 |
703,167 |
2.17 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-03-04 |
4 |
B |
$9.60 |
$43,719 |
I/I |
4,500 |
834,018 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-29 |
4 |
B |
$9.63 |
$85,356 |
I/I |
8,637 |
767,418 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-03-05 |
4 |
B |
$9.64 |
$116,133 |
I/I |
12,008 |
855,026 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-27 |
4 |
B |
$9.65 |
$143,616 |
I/I |
14,700 |
742,381 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-22 |
4 |
B |
$9.67 |
$65,218 |
I/I |
6,614 |
709,781 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-19 |
4 |
B |
$9.74 |
$95,015 |
I/I |
9,600 |
646,167 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-01 |
4 |
B |
$9.75 |
$133,207 |
I/I |
13,600 |
370,315 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-03-05 |
4 |
B |
$9.76 |
$371,681 |
I/I |
37,992 |
893,018 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-01-31 |
4 |
B |
$9.81 |
$227,815 |
I/I |
22,885 |
281,515 |
2.25 |
- |
|
95 Records found
|
|
Page 2 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|